Intellia Therapeutics and SparingVision enter strategic collaboration to develop ocular therapies
Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases. A clinical-stage genome editing